Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 178

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 178
---
 exemptions from registration. However, these shares not being registered are held by our management
and other affiliates who are limited to selling only 1% of our issued and outstanding shares every 90 days.

Our Common Stock is considered a “penny
stock” and will continue to be considered a penny stock so long as it trades below $5.00 per share and, as such, trading in our
Common Stock is subject to the requirements of Rule 15g-9 under the Securities Exchange Act of 1934. Under this rule, broker/dealers who
recommend low-priced securities to persons other than established customers and accredited investors must satisfy special sales practice
requirements. The broker/dealer must make an individualized written suitability determination for the purchaser and receive the purchaser’s
written consent prior to the transaction.

SEC regulations also require additional disclosure
in connection with any trades involving a “penny stock,” including the delivery, prior to any penny stock transaction, of
a disclosure schedule explaining the penny stock market and its associated risks. In addition, broker-dealers must disclose commissions
payable to both the broker-dealer and the registered representative and current quotations for the securities they offer. The additional
burdens imposed upon broker-dealers by such requirements may discourage broker-dealers from recommending transactions in our securities,
which could severely limit the liquidity of our securities and consequently adversely affect the market price for our securities. In addition,
few broker or dealers are likely to undertake these compliance activities. Other risks associated with trading in penny stocks could also
be price fluctuations and the lack of a liquid market. See “Risk Factors” on page 5.

<div align='center'>LEGAL MATTERS</div>

The validity of the Common Stock offered hereby
will be passed upon by Aboudi Legal Group PLLC.

<div align='center'>EXPERTS</div>

The consolidated financial statements of Revium
RX as of December 31, 2024 and for the two years in the period ended December 31, 2024, included in this prospectus and in the registration
statement have been so included in reliance on the report of Ziv Haft, BDO member firm, an independent registered public accounting firm,
appearing elsewhere herein and in the Registration Statement.

<div align='center'>108

ADDITIONAL INFORMATION</div>

We have filed with the SEC this registration statement
on Form S-1 under the Securities Act with respect to the shares of Common Stock being offered by this Prospectus. This Prospectus, which